Professor Pamela McCombe
Professor

Pamela McCombe

Email: 
Phone: 
+61 7 334 66017

Background

Neurologist

Dr McCombe graduated in Medicine from UQ and completed a Science degree for medical students. She then trained as a neurologist in Sydney, at Prince Henry and Prince of Wales Hospitals. She obtained a PhD from the University of Sydney. She obtained experience in Neurophysiology in Cleveland and then returned to UQ as a post-doctoral fellow. She worked for some years as a research fellow in Neuroimmunology and was an NHMRc SRF. Later she resumed clinical practice as a neurologist, and contimued her research as an NHMRC Practitioner Fellow. She is currentlyProfessor and Head of the Royal Brisbane Clinical school in the School of Medicine and Co-head of the Brain and Mental Health Theme at the UQ Centre for Clinical Research.

Availability

Professor Pamela McCombe is:
Available for supervision

Fields of research

Clinical sciences Immunology Statistics

Qualifications

  • Bachelor of Science, The University of Queensland
  • Bachelor of Medicine and Surgery and Medical Science, The University of Queensland
  • Doctor of Philosophy, University of Sydney
  • Royal Australasian College of Physicians, Royal Australasian College of Physicians

Research interests

  • Biomarkers and heterogeneity in ALS

    One of the challenges of ALS is understanding disease heterogeneity. Our work studies the variability of patients by detailed clinical, laboratory and genetic studies, and by identifying biomarkers that are associated with disease. We use a range of techniques including neurophysiology, MRI, metabolic studies, genetic studies, immune markers and biochemical studies including proteomics. We are using this information to analyse whether patients can be assigned into subgroups and to correlated with survival.

  • Inflammatory neuropathy studies

    This is an ongoing study of the immunological basis and genetic basis of acute and chronic inflammatory neuropathy

  • Pregnancy and MS

    This study is exploring the short and long term effects of pregnancy in multiple sclerosis. This includes the clinical effects of pregnancy and the effects on gene expression and methylation

  • Immunology of stroke

    This study involves documenting the immune responses after human stroke and determining the significance of these responses.

  • Neuromuscular disease

    This work is based at the Neuromuscular clinic at Royal Brisbane and Women's Hospital, and involves correlation of genotype and phenotype of inherited neuromuscular disease

Search Professor Pamela McCombe’s works on UQ eSpace

456 works between 1975 and 2025
All (456) Journal Article (306) Book Chapter (4) Conference Publication (143) Book (1) Other Outputs (1) Edited Outputs (1)

181 - 200 of 456 works

2019

Conference Publication

Postpartum relapse after first on-study pregnancy in RRMS patients treated with alemtuzumab in the phase 2 and 3 clinical development program over 8 years

Celius, E. G., Achiron, A., Compston, D. A. S., Derwenskus, J., Devonshire, V., Hellwig, K., Hutton, G. J., McCombe, P., Moore, M., Oh, J., Simm, R. F., Sousa, L., Vincent, S. G., Chung, L., Daizadeh, N., Mitchell, C. and Rog, D. (2019). Postpartum relapse after first on-study pregnancy in RRMS patients treated with alemtuzumab in the phase 2 and 3 clinical development program over 8 years. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm Sweden, 11-13 September 2019. London, United Kingdom: Sage Publications.

Postpartum relapse after first on-study pregnancy in RRMS patients treated with alemtuzumab in the phase 2 and 3 clinical development program over 8 years

2018

Journal Article

The short and long-term effects of pregnancy on multiple sclerosis and experimental autoimmune encephalomyelitis

McCombe, Pamela A. (2018). The short and long-term effects of pregnancy on multiple sclerosis and experimental autoimmune encephalomyelitis. Journal of Clinical Medicine, 7 (12) 494, 494. doi: 10.3390/jcm7120494

The short and long-term effects of pregnancy on multiple sclerosis and experimental autoimmune encephalomyelitis

2018

Journal Article

Association of inflammation and disability accrual in patients with progressive-onset multiple sclerosis

Hughes, Jordana, Jokubaitis, Vilija, Lugaresi, Alessandra, Hupperts, Raymond, Izquierdo, Guillermo, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grand'maison, Francois, Grammond, Pierre, Sola, Patrizia, Ferraro, DIana, Ramo-Tello, Cristina, Trojano, Maria, Slee, Mark, Shaygannejad, Vahid, Boz, Cavit, Lechner-Scott, Jeanette, Van Pesch, Vincent, Pucci, Eugenio, Solaro, Claudio, Verheul, Freek, Terzi, Murat, Granella, Franco, Spitaleri, Daniele, Alroughani, Raed, Jun, Jae-Kwan, Fambiatos, Adam, Van Der Walt, Anneke ... Hinson, Eloise (2018). Association of inflammation and disability accrual in patients with progressive-onset multiple sclerosis. JAMA Neurology, 75 (11), 1407-1415. doi: 10.1001/jamaneurol.2018.2109

Association of inflammation and disability accrual in patients with progressive-onset multiple sclerosis

2018

Conference Publication

Clinical and therapeutic predictors of relapse and disability outcomes in neuromyelitis optica spectrum disorder

Kunchok, A., Malpas, C., Horakova, D., Havrdova, E., Alroughani, R., Terzi, M., Yamout, B., Karabudak, R., Boz, C., Ozakbas, S., Olascoagam, J., Simon, M., Granellau, F., McCombe, P., Csepanym, T., Bergamaschi, R., Fragoso, Y., Al-Harbin, T., Turkoglu, R., Lechner-Scott, J., Laureys, G., Pucci, E., Sola, P., Ferraro, D., Altintas, A., Grand'Maison, F., Izquierdo, G., Eichau, S., Lugaresi, A. ... Kalincik, T. (2018). Clinical and therapeutic predictors of relapse and disability outcomes in neuromyelitis optica spectrum disorder. 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD.

Clinical and therapeutic predictors of relapse and disability outcomes in neuromyelitis optica spectrum disorder

2018

Conference Publication

Disability outcomes in patients with early cerebellar symptoms in multiple sclerosis

Le, M. V. H., Malpas, C., Sharmin, S., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Eichau, S., Ozakbas, S., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Alroughani, R., Bergamaschi, R., Sola, P., Grammond, P., Grand'Maison, F., Terzi, M., Boz, C., Hupperts, R., Butzkueven, H., Van der Walt, A., Pucci, E., Granella, F., Van Pesch, V., Soysa, A., Yamout, B., Lechner-Scott, J. ... Kalincik, T. (2018). Disability outcomes in patients with early cerebellar symptoms in multiple sclerosis. 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD.

Disability outcomes in patients with early cerebellar symptoms in multiple sclerosis

2018

Conference Publication

Early clinical predictors of severe MS

Malpas, C., Sharmin, S., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Bergamaschi, R., Sola, P., Ferraro, D., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Grand'Maison, F., Ozakbas, S., Van Pesch, V., Granella, F., Hupperts, R., Pucci, E., Boz, C., Iuliano, G., Sidhom, Y., Gouider, R., Spitaleri, D., Butzkueven, H., Soysal, A., Petersen, T., Verheul, F. ... Kalincik, T. (2018). Early clinical predictors of severe MS. 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD.

Early clinical predictors of severe MS

2018

Conference Publication

Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry

Spelman, T., Harvrdova, E. K., Horakova, D., Izquierdo, G., Kalincik, T., Lugaresi, A., Onofrj, M., Duquette, P., Girard, M., Prat, A., Grammond, P., Grand'Maison, F., Granella, F., Lechner-Scott, J., Sola, P., Ferrero, D., Sa, M. J., Terzi, M., Ozakbas, S., Van Pesch, V., Van Wijmeersch, B., Boz, C., Karabudak, R., Cartechini, E., McCombe, P. and Butzkueven, H. (2018). Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry. 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD.

Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry

2018

Conference Publication

Alemtuzumab improves clinical and MRI disease activity outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ study)

Comi, G., Arnold, D. L., Boyko, A. N., Hartung, H. -P., Havrdova, E. K., Inshasi, J. S., McCombe, P., Oreja-Guevara, C., Pelletier, D., Pozzilli, C., Selmaj, K. W., Scott, T. F., Chung, L., Daizadeh, N., Afsar, S., Nakamura, K. and Van Wijmeersch, B. (2018). Alemtuzumab improves clinical and MRI disease activity outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ study). 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD.

Alemtuzumab improves clinical and MRI disease activity outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ study)

2018

Conference Publication

Determinants of MS re-activation after discontinuing therapies

Husin, H., Wallace, J., Malpas, C., Sharmin, S., Horakova, D., Havrdova, E. Kubala, Izquierdo, G., Eichau, S., Prat, A., Girard, M., Duquette, P., Trojano, M., Grammond, P., Lugaresi, A., Onofrj, M., Ozakbas, S., Butzkueven, H., Sola, P., Ferraro, D., Alroughani, R., Grand'Maison, F., Terzi, M., Lechner-Scott, J., Boz, C., Hupperts, R., Shaygannejad, V., Bergamaschi, R., Pucci, E., Van Pesch, V. ... Kalincik, T. (2018). Determinants of MS re-activation after discontinuing therapies. 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD.

Determinants of MS re-activation after discontinuing therapies

2018

Journal Article

Genome-wide association study in Guillain-Barré syndrome

Blum, Stefan, Ji, Ying, Pennisi, David, Li, Zhixiu, Leo, Paul, McCombe, Pamela and Brown, Matthew A. (2018). Genome-wide association study in Guillain-Barré syndrome. Journal of Neuroimmunology, 323, 109-114. doi: 10.1016/j.jneuroim.2018.07.016

Genome-wide association study in Guillain-Barré syndrome

2018

Journal Article

Increased constitutive activation of NF-κB p65 (RelA) in peripheral blood cells of patients with progressive multiple sclerosis

Yan, Jun, Winterford, Clay M., Catts, Vibeke S., Pat, Betty K., Pender, Michael P., McCombe, Pamela A. and Greer, Judith M. (2018). Increased constitutive activation of NF-κB p65 (RelA) in peripheral blood cells of patients with progressive multiple sclerosis. Journal of Neuroimmunology, 320, 111-116. doi: 10.1016/j.jneuroim.2018.04.002

Increased constitutive activation of NF-κB p65 (RelA) in peripheral blood cells of patients with progressive multiple sclerosis

2018

Journal Article

Hypermetabolism in ALS is associated with greater functional decline and shorter survival

Steyn, Frederik J., Ioannides, Zara A., van Eijk, Ruben P. A., Heggie, Susan, Thorpe, Kathryn A., Ceslis, Amelia, Heshmat, Saman, Henders, Anjali K., Wray, Naomi R., van den Berg, Leonard H., Henderson, Robert D., McCombe, Pamela A. and Ngo, Shyuan T. (2018). Hypermetabolism in ALS is associated with greater functional decline and shorter survival. Journal of Neurology, Neurosurgery, and Psychiatry, 89 (10), jnnp-2017. doi: 10.1136/jnnp-2017-317887

Hypermetabolism in ALS is associated with greater functional decline and shorter survival

2018

Conference Publication

Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study)

Steingo, Brian, Oreja-Guevara, Celia, Alroughani, Raed, Brassat, David, Boyko, Alexey N., McCombe, Pamela, Van Wijmeersch, Bart, Margolin, David H., Melanson, Maria, Daizadeh, Nadia, Rodriguez, Claudio E. and Vermersch, Patrick (2018). Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study). AAN 70th Annual Meeting, Los Angeles, CA United States, 21-27 April 2018. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.90.15_supplement.p6.366

Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study)

2018

Conference Publication

Presentation of Neuromyelitis Optica (NMO) in patients from different racial groups: analysis of the global NMOBase Registry

Kister, Ilya, Bacon, Tamar, Shaygannejad, Vahid, Havrdova, Eva, Alroughani, Raed, Terzi, Murat, Altintas, Ayse, Hor, Jyh Yung, Al-Harbi, Talal, Boz, Cavit, Bergamaschi, Roberto, Ozakbas, Serkan, Ferraro, Diana, Fragoso, Yara, Laureys, Guy, Soysal, Aysun, Majdinassab, Nastaran, Onofrj, Marco, Pucci, Eugenio, Vucic, Ostoja (Steve), Slee, Mark, Lechner-Scott, Jeannette, Rojas, Juan Ignacio, Burgos, Marcos, Castillo Trivino, Tamara, Reid, Allyson, Rimler, Zoe, McCombe, Pamela, Granella, Franco ... Butzkueven, Helmut (2018). Presentation of Neuromyelitis Optica (NMO) in patients from different racial groups: analysis of the global NMOBase Registry. 70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los Angeles Ca, Apr 21-27, 2018. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Presentation of Neuromyelitis Optica (NMO) in patients from different racial groups: analysis of the global NMOBase Registry

2018

Conference Publication

Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study)

Vermersch, Patrick, Coles, Alasdair J., Boyko, Alexey N., De Seze, Jérôme, Hartung, Hans-Peter, Havrdova, Eva, Inshasi, Jihad Said, McCombe, Pamela, Montalban, Xavier, Pozzilli, Carlo, Selmaj, Krzysztof W., Margolin, David H., Melanson, Maria, Daizadeh, Nadia, Rodriguez, Claudio E. and Van Wijmeersch, Bart (2018). Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study). AAN 70th Annual Meeting, Los Angeles, CA United States, 21-27 April 2018. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.90.15_supplement.p6.376

Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study)

2018

Journal Article

A combined tract-based spatial statistics and voxel-based morphometry study of the first MRI scan after diagnosis of amyotrophic lateral sclerosis with subgroup analysis

Alruwaili, A. R., Pannek, K., Coulthard, A., Henderson, R., Kurniawan, N. D. and McCombe, P. (2018). A combined tract-based spatial statistics and voxel-based morphometry study of the first MRI scan after diagnosis of amyotrophic lateral sclerosis with subgroup analysis. Journal of Neuroradiology, 45 (1), 41-48. doi: 10.1016/j.neurad.2017.03.007

A combined tract-based spatial statistics and voxel-based morphometry study of the first MRI scan after diagnosis of amyotrophic lateral sclerosis with subgroup analysis

2018

Journal Article

Mass spectrometry analysis of plasma from amyotrophic lateral sclerosis and control subjects

Xu, Zhouwei, Lee, Aven, Nouwens, Amanda, David Henderson, Robert and Mccombe, Pamela Ann (2018). Mass spectrometry analysis of plasma from amyotrophic lateral sclerosis and control subjects. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 19 (5-6), 1-15. doi: 10.1080/21678421.2018.1433689

Mass spectrometry analysis of plasma from amyotrophic lateral sclerosis and control subjects

2018

Conference Publication

Alemtuzumab provides durable clinical efficacy in patients with active rrms in the absence of continuous treatment: 7-Year follow-up of CARE-MS I (TOPAZ Study)

Van Wijmeersch, B., Vermersch, P., Boyko, A., de Seze, J., Hartung, H. -P., Havrdova, E. Kubala, Inshasi, J. Said, McCombe, P., Montalban, X., Pozzili, C., Melanson, M., Daizadeh, N., Rodriguez, C. and Selmaj, K. (2018). Alemtuzumab provides durable clinical efficacy in patients with active rrms in the absence of continuous treatment: 7-Year follow-up of CARE-MS I (TOPAZ Study). 4th Congress of the European Academy of Neurology (EAN), Lisbon, Portugal, 16-19 June 2018. Chichester, West Sussex, United Kingdom: Wiley-Blackwell.

Alemtuzumab provides durable clinical efficacy in patients with active rrms in the absence of continuous treatment: 7-Year follow-up of CARE-MS I (TOPAZ Study)

2018

Conference Publication

Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study)

Steingo, Brian, Oreja-Guevara, Celia, Alroughani, Raed, Brassat, David, Boyko, Alexey N., McCombe, Pamela, Van Wijmeersch, Bart, Margolin, David H., Melanson, Maria, Daizadeh, Nadia, Rodriguez, Claudio E. and Vermersch, Patrick (2018). Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study). 70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los Angeles, CA, United States, Apr 21-27, 2018. Philadelphia, PA, United States: Lippincott Williams & Wilkins.

Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study)

2018

Conference Publication

Durable improvements in clinical outcomes with alemtuzumab in patients with active relapsing-remitting multiple sclerosis in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (TOPAZ study)

Inshasi, Jihad Said, Boyko, Alexey N., De Seze, Jerome, Hartung, Hans-Peter, Havrdova, Eva, McCombe, Pamela, Montalban, Xavier, Pozzilli, Carlo, Vermersch, Patrick and Margolin, David H. (2018). Durable improvements in clinical outcomes with alemtuzumab in patients with active relapsing-remitting multiple sclerosis in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (TOPAZ study). 3rd Congress of Middle East North Africa Committee for Research and Treatment in Multiple Sclerosis (MENACTRIMS), Dubai, UAE, 24-25 November 2017 . London, United Kingdom : Sage Publications.

Durable improvements in clinical outcomes with alemtuzumab in patients with active relapsing-remitting multiple sclerosis in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (TOPAZ study)

Current funding

  • 2024 - 2026
    Using a novel humanized mouse model to investigate how EBV infection at different ages potentiates development of CNS demyelinating disease
    United States Congressionally Directed Medical Research Programs - Multiple Sclerosis Research Program
    Open grant
  • 2023 - 2025
    Using a novel humanized mouse model to investigate how EBV infection at different ages potentiates development of CNS demyelinating disease
    National Multiple Sclerosis Society-US
    Open grant
  • 2023 - 2027
    How does Epstein-Barr virus infection lead to multiple sclerosis?
    NHMRC MRFF CTAI and EPCDRI Multiple Sclerosis
    Open grant
  • 2023 - 2026
    Target validation of acid-sensing ion channel inhibitors to stop disease progression and manage pain in MS
    National Multiple Sclerosis Society-US
    Open grant
  • 2022 - 2025
    Leveraging medical records to identify patients at risk of neurodegenerative disease
    Boosting Dementia Research Grants (PR4): European Union Joint Program on Neurodegenerative Disease Research (JPND) Call for Multinational Projects
    Open grant
  • 2020 - 2025
    Assessing the effects of cladribine on vaccine recall responses in multiple sclerosis.
    Merck Healthcare KGaA
    Open grant
  • 2020 - 2025
    A novel biomarker for ALS
    Cure for MND Foundation - Impact Grants
    Open grant

Past funding

  • 2023 - 2024
    An Australian Sporadic ALS transcriptome resource
    Motor Neurone Disease Research Institute of Australia Inc Innovator Grant
    Open grant
  • 2023 - 2025
    Investigating effects of Evobrutinib on immune and non-immune cells in microglia-enhanced brain organoids
    Merck Group T/A Ares Trading SA
    Open grant
  • 2022 - 2023
    Excitotoxins in the plasma of subjects with motor neurone disease
    Wesley Medical Research Ltd
    Open grant
  • 2022 - 2025
    A high-throughput system to identify ALS risk genes from genome-wide association studies
    Cure for MND Foundation - Impact Grants
    Open grant
  • 2022 - 2024
    Developing novel acid-sensing ion channel inhibitors as neuroprotective leads and diagnostic agents for multiple sclerosis
    Multiple Sclerosis Research Australia - Targeted Grant - Neurodegeneration
    Open grant
  • 2021 - 2022
    Targeting NAT1 to improve metabolism and slow disease progression in MND
    Motor Neurone Disease Research Institute of Australia Inc Innovator Grant
    Open grant
  • 2021
    Transcriptomic and Functional Evaluation of Immune-Activated Monocytes in MND
    Motor Neurone Disease Research Institute of Australia Inc Linda Rynalski Bridge Funding Grant
    Open grant
  • 2021 - 2022
    Revisiting Excitotoxicity in ALS: how does this occur?
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2021 - 2022
    N-acetyltransferase 1, a modifier of disease outcome in patients with Motor Neurone Disease (MND).
    Metro North Hospital and Health Service
    Open grant
  • 2021 - 2023
    Targeting complement C5a receptor 2 as a disease-modifying treatment for motor neuron disease
    NHMRC Development Grant
    Open grant
  • 2020 - 2021
    Possible gut derived toxins in ALS: prevalence and effects on outcome
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2020 - 2021
    Transcriptomic and Functional Evaluation of Immune-Activated Monocytes in MND.
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2020 - 2021
    Investigating the therapeutic inhibition of CXCR2 as a disease modifying treatment for motor neurone disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2020 - 2021
    Investigating the immunometabolic nature of motor neurone disease (MND): a study linking metabolism, inflammation, and clinical outcomes in MND patients
    Metro North Hospital and Health Service
    Open grant
  • 2020 - 2022
    Development of biomarkers for loss of fat free mass and disease progression in patients with Motor Neurone Disease
    Royal Brisbane and Women's Hospital
    Open grant
  • 2019 - 2020
    Immunogenetics of motor neurone disease - a pilot study
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2019 - 2020
    Investigating the beneficial effects of complement C3aR on immune cell glucose metabolism in MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2019 - 2020
    Manipulation of free fatty acid receptors to tame the immune response in MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2019 - 2022
    Multiple Sclerosis: Pregnancy and Prognosis (NHMRC Project Grant led by Monash University)
    Monash University
    Open grant
  • 2019 - 2020
    Role of NLRP3 inflammasome activation in the prognosis of secondary progressive multiple sclerosis
    Metro North Hospital and Health Service
    Open grant
  • 2018 - 2021
    A novel ephrin receptor A4-Fc fusion protein for the treatment of motor neuron disease
    Cure for MND Foundation - Translational Research Grants
    Open grant
  • 2018 - 2019
    Novel biomarkers for motor neurone disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2018 - 2021
    EATT for MND: Exposing mechanisms of impaired appetite regulation in MND
    Wesley Medical Research Ltd
    Open grant
  • 2018 - 2019
    Longitudinal assessment of behaviour and cognition in ALS through brief Online Carers' behavioural Questionnaire (OCQ)
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2018 - 2019
    Investigating the proteome of MND brains
    Metro North Hospital and Health Service
    Open grant
  • 2018
    Ion Mobility Separation of Challenging Clinical Samples
    UQ Major Equipment and Infrastructure
    Open grant
  • 2018 - 2020
    Use of mass spectrometry to identify circulating toxins in the people with ALS
    Wesley Merdical Research
    Open grant
  • 2018 - 2022
    Validating the NLRP3 Inflammasome as a Therapeutic Target in Motor Neuron Disease
    NHMRC Project Grant
    Open grant
  • 2017 - 2018
    Targeting neuromuscular stability in motor neuron disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2017 - 2018
    Cell-free DNA and ALS; insight into disease mechanisms and progression
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2017 - 2020
    Assessment of metabolic health in neurodegeneration: studies in motor neurone disease (MND)
    Wesley Medical Research Ltd
    Open grant
  • 2017
    Discovery of EAAT5 - a protein that may stop glutamate excitotoxicity in ALS
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2017 - 2019
    Does genetic variation in genes controlling pro-inflammatory immune responses modulate outcomes of MIS416 treatment in patients with multiple sclerosis?
    Wesley Medical Research Ltd
    Open grant
  • 2017 - 2018
    Metabolic exploration in neurodegenerative disease (MEND): synergy between derangements in systemic and muscle metabolism in MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2017 - 2018
    Development of triheptanoin as a treatment for motor neurone disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2017 - 2018
    A Pharmacology Screening Facility to Accelerate Drug Discovery and Development
    UQ Major Equipment and Infrastructure
    Open grant
  • 2016
    Metabolic and gut dynamics in MND: Identifying novel strategies to meet energy needs in patients
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2016
    Using biomarkers to explore heterogeneity of motor neurone disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2015
    A multicentre study of the impact of metabolic balance and dietary intake on the clinical parameters of disease progression
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2015
    Blood biomarkers in ALS: Translation into clinical practice of pNfH and search for additional biomarkers using proteomics
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2015 - 2020
    Determining the contribution of peripheral immune complement signalling in the progression of motor neuron disease
    NHMRC Project Grant
    Open grant
  • 2015
    Mass spectrometry to search for biomarkers in motor neurone disease
    Royal Brisbane and Women's Hospital
    Open grant
  • 2015 - 2016
    Therapeutic targeting of the NLRP3 inflammasome using a potent and orally active inhibitor in experimental MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2014
    Innate immune complement signalling in peripheral immune cells during the progression of motor neurone disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2014 - 2015
    Investigating the consequences of increased fat catabolism in motor neurone disease (MND)
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2014
    Investigation of a new gene involved in Motor Neurone Disease
    Royal Brisbane and Women's Hospital
    Open grant
  • 2014
    Mitochondrial analysis suite
    UQ Major Equipment and Infrastructure
    Open grant
  • 2014
    Targeting EphA4 as a treatment for MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2014 - 2015
    Whole exome sequencing of sporadic MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2013 - 2016
    A model for understanding and treating amyotrophic lateral sclerosis using induced pluripotent stem cells (An IPSC model of ALS)
    Smart Futures Fund - QCAS Biotechnology Projects Fund
    Open grant
  • 2013 - 2014
    Biomarkers of disease progression in MND
    UQ Academic Title Holder Research Fund
    Open grant
  • 2013 - 2014
    Investigating the causes and consequences of growth hormone dysfunction in motor neuron disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2013
    T cells in stroke - part of the solution?
    Royal Brisbane and Women's Hospital
    Open grant
  • 2013
    Use of biomarkers to understand Amyotrophic Lateral Sclerosis
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2013
    Using biomarkers to assess disease progression and understanding of MND
    Royal Brisbane and Women's Hospital
    Open grant
  • 2012 - 2013
    Blood Biomarkers in Motor Neurone Disease
    Royal Brisbane and Women's Hospital
    Open grant
  • 2012
    Genetic Factors that predispose to GBS and CIDP
    Royal Brisbane and Women's Hospital
    Open grant
  • 2012
    MND - not a simple disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2011 - 2012
    Role of maternofetal chimerism in transferring susceptibility to MS
    National Multiple Sclerosis Society-US
    Open grant
  • 2011
    Comprehensive assessment of MND patients as a means to studying progression and identifying disease subtypes
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2011
    Immunogenetic studies of Guillain-Barre Syndrome and chronic inflammatory demyelinating polyradiculoneuropathy
    Royal Brisbane and Women's Hospital
    Open grant
  • 2011
    Nature and timing of inflammation after acute ischaemic stroke
    Royal Brisbane and Women's Hospital
    Open grant
  • 2011 - 2013
    Nature and timing of inflammation after acute ischaemic stroke
    National Heart Foundation of Australia
    Open grant
  • 2011 - 2013
    NFKBIA mutations as a mechanism leading to constitutive activation of NF-kB in patients with primary progressive MS
    Multiple Sclerosis Research Australia
    Open grant
  • 2011 - 2013
    The role of the innate immune system during the progression of motor neuron disease; the search for new therapeutic targets
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2009
    Assessment of Disease Progression in Motor Neurone Disease
    Royal Brisbane & Women's Hospital Research Foundation
    Open grant
  • 2009 - 2012
    Development of a new method of motor unit number estimation for use in motor neurone disease
    NHMRC Project Grant
    Open grant
  • 2009 - 2010
    Identifying biomarkers for MND using flow cytometry.
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2009 - 2011
    The effects of pregnancy and the post-partum period on T cells, antibodies, and gene expression in EAE
    Multiple Sclerosis Research Australia
    Open grant
  • 2008 - 2012
    Immune Response to stroke
    Wesley Merdical Research
    Open grant
  • 2006 - 2008
    Characterisation of peripheral immune response to ischaemic stroke
    Royal Brisbane Hospital
    Open grant
  • 2005 - 2006
    Start-up Grant
    Royal Brisbane & Women's Hospital Research Foundation
    Open grant
  • 2002 - 2004
    Motor Unit Analysis in Motor Neurone Disease
    Motor Neurone Disease Association Queensland Inc
    Open grant
  • 2000 - 2003
    Early pregnancy factor and experimental autoimmune encephalomyelitis
    National Multiple Sclerosis Society-US
    Open grant
  • 1999
    A study of T cell reactivity in patients with Guillain-Barre Syndrome and chronic inflammatory demyelinating polyneuropathy
    Royal Australasian College of Physicians
    Open grant
  • 1999 - 2001
    Correlation Between Ganglioside-Specific Immune Responses and Disease Prograssion in Multiple Sclerosis
    NHMRC Project Grant
    Open grant
  • 1999
    T Cells and cytokines in inflammatory neuropathy
    Mayne Bequest Fund
    Open grant
  • 1999 - 2000
    The use of early pregnancy factor as treatment for experimental autoimmune encephalomyelitis
    National Multiple Sclerosis Society of Australia
    Open grant
  • 1998
    Early Pregnancy Factor and Experimental Autoimmune Encephalomyelitis
    Mayne Bequest Fund
    Open grant
  • 1996 - 1998
    Studies of T cell reactivity to myelin antigens in multiple sclerosis
    NHMRC Project Grant
    Open grant
  • 1996 - 2000
    Studies of the mechanisms of relapse of experimental autoimmune encephalomyelitis
    NHMRC Project Grant - 5 Yr Extended with Fellow
    Open grant
  • 1995 - 1997
    Modulation of autoreactive T cell apoptosis in experimental autoimmune encephalomyelitis
    NHMRC Project Grant - Standard
    Open grant

Availability

Professor Pamela McCombe is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Completed supervision

Enquiries

For media enquiries about Professor Pamela McCombe's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au